🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Cardiff Oncology, Inc.

CRDF Healthcare
$0.88 $-0.03 (-3.15%)
Market Cap: $68.47 M
Gurus Holding
3
Popularity Rank
#2869
% of Shares Held
0.50%
Net Activity (Q2 2026)
+$287,651.19

Guru Ownership Trend

Guru Analysis for Cardiff Oncology, Inc. (CRDF)

Cardiff Oncology, Inc. (CRDF), a key player in the Healthcare sector, continues to attract institutional attention.

As of Q2 2026, a total of 3 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $342,077.27.

Top institutional holders include Cliff Asness and Steven Cohen.

Institutional sentiment is currently Bullish. This is evidenced by a $287,651.19 net inflow during the quarter.

Recent activity highlights Cliff Asness who increased their stake by 423.5%. Conversely, Renaissance Technologies (RenTech) reduced exposure by 86.2%.

Key Holders

Top 5 by Value

Top 5 by Conviction

Recent Activity Breakdown (Q2 2026)

+$401,157.99
Total Buy Value
New Buys 1
Additions 1
-$113,506.8
Total Sell Value
Reductions 1
Sold Out 0

Guru Consensus (Q2 2026)

Based on recent activity
Net Sellers
1
Net Buyers
2

FAQs for Cardiff Oncology, Inc. (CRDF)

Major holders include Cliff Asness ($450,260), Steven Cohen ($36,901), Renaissance Technologies (RenTech) ($18,125). According to the latest reported data, 3 tracked investment managers collectively hold approximately 388,680 shares.

According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $287,651.19, with 2 managers increasing positions and 1 managers reducing holdings.

During the most recent reporting period, 1 managers trimmed their positions, while 0 fully exited CRDF. The total reported sell value was $113,506.8.

Yes, 1 managers opened new positions in CRDF, and 1 increased their existing holdings. The total reported buy value was $401,157.99.

Portfolio Manager % Portfolio Activity Shares Value Report Date
0.00% Add 423.5% 346,353 $450,260 Q2 2026
0.00% New Buy 28,385 $36,901 Q2 2026
0.00% Reduce -86.2% 13,942 $18,125 Q2 2026
Date
Insider Name
Transaction
Value
Shares
Position / Chg
SEC Form